Alberto Zanchetti

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9477745/alberto-zanchetti-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 416
 55,286
 88
 232

 papers
 citations
 h-index
 g-index

 493
 63,587
 4
 6.91

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
416	Different effects of antihypertensive treatment on office and ambulatory blood pressure: a meta-analysis. <i>Journal of Hypertension</i> , 2019 , 37, 467-475	1.9	10
415	Estimation of metabolic syndrome heritability in three large populations including full pedigree and genomic information. <i>Human Genetics</i> , 2019 , 138, 739-748	6.3	2
4 ¹ 4	Blood Pressure-Lowering Treatment and the Prevention of Heart Failure: Differences and Similarities of Antihypertensive Drug Classes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019 , 285-298	0.1	
413	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. <i>Journal of Hypertension</i> , 2019 , 37, 1126-1147	1.9	17
412	What Is New and What Is Different in Recent Guidelines on Antihypertensive Treatment? Looking Forward to Guidelines Reappraisal. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 839-85	1 ^{0.1}	
411	Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 1222-1236	1.9	36
410	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698
409	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. <i>Journal of Hypertension</i> , 2018 , 36, 1637-1647	1.9	38
408	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. <i>PLoS Medicine</i> , 2018 , 15, e1002538	11.6	44
407	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2018 ,	1.9	28
406	36, 1622-1636 Best antihypertensive strategies to improve blood pressure control in Latin America: position of the Latin American Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 208-220	1.9	5
405	Osmotic indices and kidney concentrating activity: population-based data on correlates and prognostic power. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 274-283	4.3	4
404	MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018 , 8, e02	2∳038	20
403	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the	1.9	1262
402	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017 , 42, 198-225	17.1	13
401	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2017 , 35, 922-944	1.9	124
400	Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2017 , 35, 2150-2160	1.9	52

(2016-2017)

399	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2017 , 35, 2138-2149	1.9	13
398	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. <i>JAMA Internal Medicine</i> , 2017 , 177, 1498-1505	11.5	98
397	Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma. <i>Hypertension</i> , 2017 , 70, 412-419	8.5	10
396	From pregnancy to childhood and adulthood: the trajectory of hypertension. <i>Journal of Hypertension</i> , 2016 , 34, 1235-6	1.9	
395	Challenges of antihypertensive treatment. <i>Journal of Hypertension</i> , 2016 , 34, 1449-50	1.9	
394	Reply. Journal of Hypertension, 2016 , 34, 2103-4	1.9	
393	Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets? Position Statement of the Latin American Society of Hypertension. <i>Hypertension</i> , 2016 , 68, 257-62	8.5	14
392	Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016 , 34, 613-22	1.9	182
391	Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular	1.9	89
390	variability. <i>Journal of Hypertension</i> , 2016 , 34, 1665-77 Prediction and prevention of hypertension-related events. <i>Journal of Hypertension</i> , 2016 , 34, 591-2	1.9	
389	Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016 , 34, 813-21	1.9	97
388	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failuremeta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016 , 34, 373-84; discussion 384	1.9	47
387	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , 2016 , 37, 955-64	9.5	68
386	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , 2016 , 25, 83-92	1.7	41
385	From inflammation to renal denervation in hypertension research. <i>Journal of Hypertension</i> , 2016 , 34, 2301-2302	1.9	
384	Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events - meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016 , 34, 1451-63	1.9	41
383	2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. <i>Journal of Hypertension</i> , 2016 , 34, 1887-920	1.9	582
382	Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. Journal of Hypertension 2016, 34, 1921-32	1.9	54

381	Prediction, diagnosis and treatment of hypertension. <i>Journal of Hypertension</i> , 2016 , 34, 1025-6	1.9	
380	Antihypertensive treatment is not a risk factor for major cardiovascular events in the Gubbio residential cohort study. <i>Journal of Hypertension</i> , 2015 , 33, 736-44; discussion 744	1.9	10
379	Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugsoverview and meta-analyses. <i>Journal of Hypertension</i> , 2015 , 33, 195-2	2119	163
378	Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. <i>Circulation Research</i> , 2015 , 116, 1058-73	15.7	101
377	Lercanidipine in worldwide usage. Current Medical Research and Opinion, 2015, 31, 161-2	2.5	
376	Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. <i>Journal of Hypertension</i> , 2015 , 33, 1321-41	1.9	85
375	Large and small vessel disease and other aspects of hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 2371-2	1.9	
374	Population-based dose-response curve of glomerular filtration rate to dietary protein intake. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1156-62	4.3	13
373	White Coat Hypertension 2015 ,		2
372	White Coat Hypertension: The History of the Irresistible, Resistible Ascent of a Misnomer 2015 , 137-147	7	1
37 ²	White Coat Hypertension: The History of the Irresistible, Resistible Ascent of a Misnomer 2015 , 137-147. White Coat Hypertension: To Treat or Not to Treat 2015 , 123-135	7	1
		8.5	1 40
371	White Coat Hypertension: To Treat or Not to Treat 2015, 123-135 Effect of long-term antihypertensive treatment on white-coat hypertension. <i>Hypertension</i> , 2014,		
37 ¹ 37 ⁰	White Coat Hypertension: To Treat or Not to Treat 2015, 123-135 Effect of long-term antihypertensive treatment on white-coat hypertension. <i>Hypertension</i> , 2014, 64, 1388-98 Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014,	8.5	40
371 370 369	White Coat Hypertension: To Treat or Not to Treat 2015, 123-135 Effect of long-term antihypertensive treatment on white-coat hypertension. <i>Hypertension</i> , 2014, 64, 1388-98 Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014, 176, 219-26 Typical and atypical coronary heart disease deaths and their different relationships with risk	8.5	40 45
37 ¹ 37 ⁰ 369 368	White Coat Hypertension: To Treat or Not to Treat 2015, 123-135 Effect of long-term antihypertensive treatment on white-coat hypertension. <i>Hypertension</i> , 2014, 64, 1388-98 Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014, 176, 219-26 Typical and atypical coronary heart disease deaths and their different relationships with risk factors. The Gubbio residential cohort study. <i>International Journal of Cardiology</i> , 2014, 173, 300-4 Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all	8.5 3.2 3.2	40 45 12
371 370 369 368 367	White Coat Hypertension: To Treat or Not to Treat 2015, 123-135 Effect of long-term antihypertensive treatment on white-coat hypertension. <i>Hypertension</i> , 2014, 64, 1388-98 Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014, 176, 219-26 Typical and atypical coronary heart disease deaths and their different relationships with risk factors. The Gubbio residential cohort study. <i>International Journal of Cardiology</i> , 2014, 173, 300-4 Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort. <i>International Journal of Cardiology</i> , 2014, 171, 361-7 Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese	8.5 3.2 3.2	40 45 12 30

363	Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. <i>European Heart Journal</i> , 2014 , 35, 299-306	9.5	17
362	Diabetes: Measuring interarm blood pressure differences in diabetes. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 387-8	15.2	2
361	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014 , 23, 3-16	1.7	474
360	Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors. <i>Journal of Hypertension</i> , 2014 , 32, 1970-8; discussion 1978	1.9	2
359	Investigating multiple aspects of blood pressure control. <i>Journal of Hypertension</i> , 2014 , 32, 1157-8	1.9	
358	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. <i>Journal of Hypertension</i> , 2014 , 32, 1741-50	1.9	31
357	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2014 , 32, 1359-66	1.9	547
356	Predictive medicine, pathophysiology and therapeutics. <i>Journal of Hypertension</i> , 2014 , 32, 1725-6	1.9	
355	From pathophysiology to therapeutic interventions: the span of hypertension research. <i>Journal of Hypertension</i> , 2014 , 32, 703-5	1.9	
354	Challenges of hypertension and hypertension treatment. <i>Journal of Hypertension</i> , 2014 , 32, 1917-8	1.9	
353	Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levelsoverview and meta-analyses of randomized trials. Journal of Hypertension, 2014 , 32, 2296-304	1.9	116
352	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2014 , 32, 2285-95	1.9	169
351	Heritability of blood pressure through latent curve trajectories in families from the Gubbio population study. <i>Journal of Hypertension</i> , 2014 , 32, 2179-87	1.9	6
350	Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension. <i>Journal of Hypertension</i> , 2014 , 32, 495-508	1.9	10
349	Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular riskoverview and meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2014 , 32, 2305-14	1.9	81
348	Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. <i>Journal of Hypertension</i> , 2014 , 32, 1551-2	1.9	12
347	RESIDUAL RISK AND RESISTANCE TO THE BENEFITS OF ANTIHYPERTENSIVE TREATMENT 2014 , 543-5	52	
346	Patients with prehypertension - do we have enough evidence to treat them?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 586-97	3.3	1

345	Gull de prlitica clilica de la ESH/ESC para el manejo de la hipertensili arterial (2013). <i>Hipertension Y Riesgo Vascular</i> , 2013 , 30, 4-91	0.5	7
344	Calcium Channel Blockers in Hypertension 2013 , 204-218		2
343	Gull de prlitica clilica de la ESH/ESC para el manejo de la hipertensili arterial (2013). <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 880.e1-880.e64	1.5	13
342	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2013 , 22, 193-2	7.8 ₇	286
341	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
340	What to look for in the current issue?. Journal of Hypertension, 2013, 31, 431-2	1.9	1
339	An outlook on the content of this journal issue. <i>Journal of Hypertension</i> , 2013 , 31, 1059-60	1.9	
338	Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. <i>Journal of Hypertension</i> , 2013 , 31, 2165-75	1.9	17
337	Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats. <i>Journal of Hypertension</i> , 2013 , 31, 1618-28	1.9	4
336	European Society of Hypertension position paper on ambulatory blood pressure monitoring. Journal of Hypertension, 2013 , 31, 1731-68	1.9	898
335	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363
334	What really matters is not what the authors meant to say, it is how their work is read. <i>Journal of Hypertension</i> , 2013 , 31, 1499-501	1.9	
333	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2013 , 31, 1925-38	1.9	635
332	Contributions to management of hypertension from papers in the current issue. <i>Journal of Hypertension</i> , 2013 , 31, 845-7	1.9	
331	Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. <i>Journal of Hypertension</i> , 2013 , 31, 223-38	1.9	46
330	Reply to blood pressure target in chronic kidney disease. <i>Journal of Hypertension</i> , 2013 , 31, 2321-2	1.9	1
329	Blood pressure and opera. <i>Journal of Hypertension</i> , 2013 , 31, 427	1.9	
328	Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. <i>Lancet, The</i> , 2012 , 379, 1602-	120	629

(2010-2012)

327	Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. <i>American Journal of Cardiology</i> , 2012 , 109, 685-92	3	131
326	Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. <i>Circulation</i> , 2012 , 126, 569-78	16.7	111
325	Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. <i>Journal of Hypertension</i> , 2012 , 30, 2213-22	1.9	21
324	Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. <i>Journal of Hypertension</i> , 2012 , 30, 1468-77	1.9	16
323	Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. <i>Journal of Hypertension</i> , 2012 , 30, 1241-51	1.9	68
322	Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. <i>Journal of Hypertension</i> , 2012 , 30, 1065-74	1.9	62
321	Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?. <i>Journal of Hypertension</i> , 2012 , 30, 2202-12	1.9	13
320	Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. <i>Journal of Hypertension</i> , 2012 , 30, 67-74	1.9	30
319	Residual Risk in Treated Hypertension 2012 , 309-321		1
318	Is hypertension a fatal disease today? Proceedings of a satellite symposium held during the 21st European Meeting on Hypertension and Cardiovascular Prevention Milan (Italy), June 17-20, 2011. Foreword. <i>Journal of Hypertension</i> , 2011 , 29 Suppl 1, S1	1.9	2
317	The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. <i>Journal of Hypertension</i> , 2011 , 29, 4-16	1.9	158
316	Is a systolic blood pressure target . <i>European Heart Journal</i> , 2011 , 32, 1500-8	9.5	88
315	Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better?. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S304-7	14.6	22
314	Guās Latinoamericanas de Hipertensiā Arterial. <i>Revista Chilena De Cardiolog</i> ā, 2010 , 29,	0.3	5
313	Electrical carotid baroreceptor stimulation in resistant hypertension. <i>Hypertension</i> , 2010 , 55, 607-9	8.5	13
312	Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. <i>PLoS Genetics</i> , 2010 , 6, e1001177	6	255
311	Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. <i>European Heart Journal</i> , 2010 , 31, 2837-40	9.5	50
310	Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. <i>BMJ, The</i> , 2010 , 340, c1197	5.9	38

309	Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 956-65	15.1	127
308	Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. <i>Journal of Hypertension</i> , 2010 , 28, 2016-25	1.9	13
307	Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. <i>Journal of Hypertension</i> , 2010 , 28, 2342-50	1.9	31
306	Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. <i>Journal of Hypertension</i> , 2010 , 28, 1593-4	1.9	2
305	Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). <i>Circulation</i> , 2009 , 120, 1084-90	16.7	97
304	Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?. <i>Journal of Human Hypertension</i> , 2009 , 23, 728-34	2.6	60
303	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009 , 27, 2121-58	1.9	1004
302	Left and right ventricular structural changes in obese hypertensives. <i>Blood Pressure</i> , 2009 , 18, 23-9	1.7	11
301	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009 , 18, 308-47	1.7	186
300	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The,</i> 2009 , 373, 1849-60	40	2427
299	Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril. <i>Journal of Hypertension</i> , 2009 , 27, 626-32	1.9	11
298	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009 , 27, 673-9	1.9	45
297	Is retinal arteriolar-venular ratio associated with cardiac and extracardiac organ damage in essential hypertension?. <i>Journal of Hypertension</i> , 2009 , 27, 1277-83	1.9	30
296	Latin American guidelines on hypertension. Latin American Expert Group. <i>Journal of Hypertension</i> , 2009 , 27, 905-22	1.9	71
295	Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. <i>Journal of Hypertension</i> , 2009 , 27, 1509-20	1.9	67
294	When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. <i>Journal of Hypertension</i> , 2009 , 27, 923-34	1.9	188
293	Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2009 , 27, 1719-42	1.9	504
292	Prevalence and clinical correlates of right ventricular hypertrophy in essential hypertension. Journal of Hypertension, 2009, 27, 854-60	1.9	26

(2008-2009)

291	Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height(2.7). <i>Journal of Hypertension</i> , 2009 , 27, 2465-71	1.9	27
290	Twenty-year cardiovascular and all-cause mortality trends and changes in cardiovascular risk factors in Gubbio, Italy: the role of blood pressure changes. <i>Journal of Hypertension</i> , 2009 , 27, 266-74	1.9	18
289	The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations. <i>Journal of Hypertension</i> , 2009 , 27, 1-2	1.9	4
288	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. <i>Blood Pressure</i> , 2008 , 17, 170-	7 ^{1.7}	10
287	The 24 h blood pressure-R-R interval relation in ambulatory monitoring. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2008 , 139, 68-77	2.4	4
286	Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?. <i>American Journal of Hypertension</i> , 2008 , 21, 458-63	2.3	26
285	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2008 , 26, 1505-26	1.9	578
284	Metabolic syndrome and target organ damage: role of blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 731-43	2.5	13
283	Metabolic syndrome and multiple organ damage in essential hypertension. <i>Blood Pressure</i> , 2008 , 17, 195-203	1.7	15
282	Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. <i>Archives of Internal Medicine</i> , 2008 , 168, 617-24		74
281	The Hyper-Pract Study: a multicentre survey on the accuracy of the echocardiographic assessment of hypertensive left ventricular hypertrophy in clinical practice. <i>Blood Pressure</i> , 2008 , 17, 124-8	1.7	12
280	Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. <i>Journal of Hypertension</i> , 2008 , 26, 357-67	1.9	58
279	Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. <i>Journal of Hypertension</i> , 2008 , 26, 164-8	1.9	24
278	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. <i>Journal of Hypertension</i> , 2008 , 26, 403-11	1.9	151
277	Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study. <i>Journal of Hypertension</i> , 2008 , 26, 18	01:-8	24
276	Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure. <i>Blood Pressure Monitoring</i> , 2008 , 13, 7-13	1.3	14
275	Introduction: avancēs rēentes dans la prūention des maladies cardiovasculaires chez le patient diabĒique. <i>Journal of Hypertension</i> , 2008 , 26, S1-S2	1.9	
274	Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients. <i>Blood Pressure Monitoring</i> , 2008 , 13, 318-24	1.3	21

273	Introduction: Advances in the prevention of cardiovascular disease in patients with diabetes. <i>Journal of Hypertension</i> , 2008 , 26, S1-S2	1.9	
272	Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. <i>Vascular Health and Risk Management</i> , 2008 , 4, 67-73	4.4	18
271	Calcium Channel Blockers in Hypertension 2007 , 268-285		
270	Management of hypertension in patients with left ventricular hypertrophy. <i>Current Hypertension Reports</i> , 2007 , 9, 498-505	4.7	6
269	Ambulatory blood pressure, target organ damage and aortic root size in never-treated essential hypertensive patients. <i>Journal of Human Hypertension</i> , 2007 , 21, 531-8	2.6	35
268	Where is hypertension research going?. <i>Journal of Hypertension</i> , 2007 , 25, 1-3	1.9	1
267	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2007 , 25, 1105-87	1.9	3825
266	Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. <i>Hypertension</i> , 2007 , 49, 40-7	8.5	194
265	Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. <i>Journal of Hypertension</i> , 2007 , 25, 1473-9	1.9	56
264	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1751-62	1.9	871
263	Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 2007 , 25, 1087-94	1.9	46
262	Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: impact of sex and age. <i>Blood Pressure Monitoring</i> , 2007 , 12, 101-6	1.3	36
261	Journal of Hypertension. Introduction. <i>Journal of Hypertension</i> , 2007 , 25, S1-2	1.9	
260	How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring?. <i>Journal of Hypertension</i> , 2007 , 25, 315-20	1.9	18
259	Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. Journal of Hypertension, 2007 , 25, 2158-67	1.9	54
258	Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension. <i>Current Hypertension Reviews</i> , 2007 , 3, 89-92	2.3	
257	Blood pressure control in Italy: results of recent surveys on hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1491-8	1.9	103
256	Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. <i>Journal of Hypertension</i> , 2007 , 25, 2463-70	1.9	62

255	Age and target organ damage in essential hypertension: role of the metabolic syndrome. <i>American Journal of Hypertension</i> , 2007 , 20, 296-303	2.3	52
254	Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. <i>American Journal of Hypertension</i> , 2007 , 20, 678-85	2.3	43
253	Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus. <i>Clinical Therapeutics</i> , 2007 , 29, S44-S53	3.5	2
252	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Blood Pressure</i> , 2007 , 16, 135-232	1.7	247
251	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2007 , 28, 1462-536	9.5	1418
250	The 2003 Guidelines for the Management of Hypertension of the European Society of Hypertension and European Society of Cardiology 2007 , 1177-1184		
249	Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes 2007 , 211	-218	5
248	Carotid atherosclerosis and cardiovascular risk stratification: role and cost-effectiveness of echo-Doppler examination in untreated essential hypertensives. <i>Blood Pressure</i> , 2006 , 15, 333-9	1.7	2
247	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. <i>Hypertension</i> , 2006 , 48, 385-91	8.5	114
246	Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7 Suppl 1, S8-11	3	3
245	Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. <i>Hypertension</i> , 2006 , 47, 56-61	8.5	42
244	Nocturnal non-dipping pattern in untreated hypertensives at different cardiovascular risk according to the 2003 ESH/ESC guidelines. <i>Blood Pressure</i> , 2006 , 15, 37-44	1.7	16
243	Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. <i>Blood Pressure</i> , 2006 , 15, 71-9	1.7	45
242	Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. <i>Blood Pressure</i> , 2006 , 15, 107-15	5 ^{1.7}	5
241	Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension. <i>Drugs</i> , 2006 , 66, 1107-15	12.1	17
240	Nebivolol in Hypertension and Chronic Heart Failure. <i>Drugs</i> , 2006 , 66, 1410	12.1	
239	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. <i>Journal of Hypertension</i> , 2006 , 24, 1405-12	1.9	119

237	Hypertensive myocardial fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 20-3	4.3	63
236	Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. Journal of Hypertension, 2006 , 24, 647-53	1.9	61
235	Hypertension: which aspects of hypertension should we impact on and how?. <i>Journal of Hypertension</i> , 2006 , 24, S2-5	1.9	10
234	Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. <i>Journal of Hypertension</i> , 2006 , 24, 167	1 1 79	42
233	New-onset diabetes and antihypertensive drugs. <i>Journal of Hypertension</i> , 2006 , 24, 3-10	1.9	209
232	Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. <i>Journal of Hypertension</i> , 2006 , 24, 603-10	1.9	148
231	FEVER study: a trial further supporting the concept of a blood pressure-independent stroke protective effect by dihydropyridines. <i>Journal of Hypertension</i> , 2006 , 24, 1215-1216	1.9	3
230	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. <i>Journal of Hypertension</i> , 2006 , 24, 2163-8	1.9	110
229	Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005 , 15, 426-40	4.5	36
228	Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). <i>American Journal of Hypertension</i> , 2005 , 18, 1052-9	2.3	128
227	Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. American Journal of Hypertension, 2005 , 18, 1282-7	2.3	29
226	Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. <i>Journal of Hypertension</i> , 2005 , 23, 1099-106	1.9	20
225	Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. <i>Journal of Hypertension</i> , 2005 , 23, 1589-95	1.9	20
224	Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study. <i>Journal of Hypertension</i> , 2005 , 23, 1203-9	1.9	7
223	Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 2005 , 23, 1047-54	1.9	23
222	The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. <i>Journal of Hypertension</i> , 2005 , 23, 2157-72	1.9	269
221	Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2005 , 23, 557-62	1.9	11
220	Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2005 , 23, 1091-8	1.9	22

(2004-2005)

219	Evidence-based medicine in hypertension: what type of evidence?. <i>Journal of Hypertension</i> , 2005 , 23, 1113-20	1.9	42
218	Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. <i>Journal of Hypertension</i> , 2005 , 23, 2269-76	1.9	98
217	Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. <i>Blood Pressure Monitoring</i> , 2005 , 10, 175-80	1.3	14
216	Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. <i>Journal of Hypertension</i> , 2005 , 23, 875-82	1.9	83
215	The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. <i>Blood Pressure</i> , 2005 , 14, 31-7	1.7	64
214	Prevalence of home blood pressure measurement among selected hypertensive patients: results of a multicenter survey from six hospital outpatient hypertension clinics in Italy. <i>Blood Pressure</i> , 2005 , 14, 251-6	1.7	48
213	The VALUE Trial 2005 , 366-375		
212	Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. <i>Blood Pressure</i> , 2004 , 13, 144-51	1.7	14
211	Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. <i>Blood Pressure</i> , 2004 , 1, 17-32	1.7	57
210	Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. <i>Circulation</i> , 2004 , 110, 552-7	16.7	135
209	Looking back, looking forward. <i>Journal of Hypertension</i> , 2004 , 22, 1-2	1.9	9
208	Relation of urinary albumin excretion to coronary heart disease and low renal function: role of blood pressure. <i>Kidney International</i> , 2004 , 65, 2290-7	9.9	16
207	Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the Assessment Prognostic Risk Observational Survey (APROS). <i>Journal of Human Hypertension</i> , 2004 , 18, 891-6	2.6	53
206	Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome?. <i>Blood Pressure</i> , 2004 , 13, 230-5	1.7	15
205	Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLISa randomized double-blind trial. <i>Stroke</i> , 2004 , 35, 2807-12	6.7	121
204	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). Journal of the American College of Cardiology, 2004 , 44, 1175-80	15.1	61
203	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet, The</i> , 2004 , 363, 2022-31	40	2112
202	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. <i>Lancet, The</i> , 2004 , 363, 2049-51	40	472

201	On the importance of estimating renal function for cardiovascular risk assessment. <i>Journal of Hypertension</i> , 2004 , 22, 1635-9	1.9	16
200	The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. <i>Journal of Hypertension</i> , 2004 , 22, 1605-12	1.9	74
199	Design of the Syst-Eur trial and Syst-Eur Phase 2: Thomas Weihrauch@contributions. <i>Journal of Hypertension</i> , 2004 , 22, 1631-2	1.9	
198	Latin American consensus on diabetes mellitus and hypertension. <i>Journal of Hypertension</i> , 2004 , 22, 22	2 9.4 1	11
197	High prevalence of retinal vascular changes in never-treated essential hypertensives: an inter- and intra-observer reproducibility study with non-mydriatic retinography. <i>Blood Pressure</i> , 2004 , 13, 25-30	1.7	25
196	Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. <i>Journal of Hypertension</i> , 2004 , 22, 273-80	1.9	149
195	Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2004 , 22, 1201-12	1.9	31
194	Metabolic syndrome and target organ damage in untreated essential hypertensives. <i>Journal of Hypertension</i> , 2004 , 22, 1991-8	1.9	137
193	Retinal microvascular changes and target organ damage in untreated essential hypertensives. Journal of Hypertension, 2004 , 22, 2095-102	1.9	64
192	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. <i>Journal of Hypertension</i> , 2004 , 22, 847-57	1.9	147
191	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE). <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1175-1180	15.1	135
190	Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2073-82	27.4	517
189	The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. <i>Journal of Hypertension</i> , 2003 , 21, 875-86	1.9	1034
188	Left ventricular hypertrophy in treated hypertensive patients with good blood pressure control outside the clinic, but poor clinic blood pressure control. <i>Journal of Hypertension</i> , 2003 , 21, 1575-81	1.9	20
187	International Society of Hypertension (ISH). Journal of Hypertension, 2003, 21, 649-650	1.9	30
186	Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?. <i>Journal of Hypertension</i> , 2003 , 21, 797-804	1.9	77
185	Costs of implementing recommendations on hypertension management given in recent guidelines. Journal of Hypertension, 2003 , 21, 2207-9	1.9	7
184	Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan. <i>Blood Pressure</i> , 2003 , 2, 5-15	1.7	8

(2002-2003)

183	Translating worldwide calcium-channel blocker experience into clinical practice. <i>Clinical Cardiology</i> , 2003 , 26, 1-2	3.3	78
182	Emerging data on calcium-channel blockers: the COHORT study. Clinical Cardiology, 2003, 26, II17-20	3.3	14
181	Non-dipper treated hypertensive patients do not have increased cardiac structural alterations. <i>Cardiovascular Ultrasound</i> , 2003 , 1, 1	2.4	30
180	Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. <i>Clinical Endocrinology</i> , 2003 , 58, 316-22	3.4	10
179	VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. <i>American Journal of Hypertension</i> , 2003 , 16, 544-8	2.3	84
178	Results of antihypertensive treatment trials in the elderly. <i>The American Journal of Geriatric Cardiology</i> , 2002 , 11, 41-7, 57		5
177	Cardiac and renal damage in the elderly hypertensive. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002 , 3 Suppl 1, S16-24	3	2
176	Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. <i>Circulation</i> , 2002 , 106, 2422-7	16.7	439
175	Neuronal nitric oxide synthase and renin stimulation by sodium deprivation are dependent on the renal nerves. <i>Journal of Hypertension</i> , 2002 , 20, 2039-45	1.9	6
174	Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: a validation study. <i>Journal of Hypertension</i> , 2002 , 20, 1589-96	1.9	12
173	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002 , 20, 1855-64	1.9	90
172	Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. <i>Journal of Hypertension</i> , 2002 , 20, 1015-22	1.9	52
171	Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. <i>Journal of Hypertension</i> , 2002 , 20, 2293-300	1.9	90
170	Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. <i>Journal of Hypertension</i> , 2002 , 20, 1307-14	1.9	122
169	Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?. <i>Journal of Hypertension</i> , 2002 , 20, 2099-110	1.9	92
168	Factors influencing acute ischaemia-induced renal hypertension in rats. <i>Journal of Hypertension</i> , 2002 , 20, 2453-63	1.9	3
167	Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. <i>Archives of Internal Medicine</i> , 2002 , 162, 582-6		79
166	Coping with the challenges of the next four years. <i>Journal of Hypertension</i> , 2002 , 20, 1-2	1.9	4

165	Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. <i>Journal of Hypertension</i> , 2002 , 20, 2301-7	1.9	48
164	Cognitive function and health-related quality of life in elderly patients with hypertension-baseline data from the study on cognition and prognosis in the elderly (SCOPE). <i>Blood Pressure</i> , 2002 , 11, 157-65	1.7	31
163	Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. <i>American Journal of Hypertension</i> , 2002 , 15, 932-40	2.3	86
162	Red blood cell count in short-term prediction of cardiovascular disease incidence in the Gubbio population study. <i>Acta Cardiologica</i> , 2002 , 57, 177-85	0.9	26
161	Impact of the Gubbio population study on community control of blood pressure and hypertension. Gubbio Study Research Group. <i>Journal of Hypertension</i> , 2001 , 19, 843-50	1.9	31
160	Transient but not sustained blood pressure increments by occupational noise. An ambulatory blood pressure measurement study. <i>Journal of Hypertension</i> , 2001 , 19, 1021-7	1.9	40
159	Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 642-50	3.1	43
158	The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. <i>Current Hypertension Reports</i> , 2001 , 3, 350-9	4.7	13
157	Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. <i>Hypertension</i> , 2001 , 37, 12-18	8.5	156
156	Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). <i>Circulation</i> , 2001 , 104, 1385-92	16.7	371
155	Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. <i>Blood Pressure</i> , 2001 , 10, 83-91	1.7	73
154	Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study. <i>Acta Cardiologica</i> , 2001 , 56, 243-51	0.9	39
153	Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. <i>Journal of Hypertension</i> , 2001 , 19, 1539-45	1.9	120
152	Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. <i>Journal of Hypertension</i> , 2001 , 19, 819-25	1.9	36
151	Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. <i>Journal of Hypertension</i> , 2001 , 19, 1149-59	1.9	99
150	Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2001 , 19, 1981-9	1.9	203
149	High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. Journal of Hypertension, 2001 , 19, 2063-70	1.9	190
148	Cardiovascular risk stratification in hypertensive patients: impact of echocardiography and carotid ultrasonography. <i>Journal of Hypertension</i> , 2001 , 19, 375-80	1.9	22

147	Role of the renal nerves in the control of renin synthesis during different sodium intakes in the rat. <i>Journal of Hypertension</i> , 2001 , 19, 1271-7	1.9	10
146	Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian	1.9	87
145	Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 218-225	12.7	329
144	Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. <i>Journal of Hypertension</i> , 2001 , 19, 2106	1.9	
143	Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. <i>Journal of Hypertension</i> , 2000 , 18, 629-42	1.9	73
142	Prevalence of target organ damage in treated hypertensive patients: different impact of clinic and ambulatory blood pressure control. <i>Journal of Hypertension</i> , 2000 , 18, 803-9	1.9	23
141	Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. <i>Journal of Hypertension</i> , 2000 , 18, 1691-9	1.9	63
140	Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2000 , 18, 197-201	1.9	110
139	Effects of a reversible QephrectomyQon renal sympathetic activity and blood pressure in the rat: evidence for an acute angiotensin-mediated hypertension. <i>Journal of Hypertension</i> , 2000 , 18, 1277-87	1.9	7
138	Guidelines for the use of self-blood pressure monitoring: a summary report of the First International Consensus Conference. Groupe Evaluation & Measure of the French Society of Hypertension. <i>Journal of Hypertension</i> , 2000 , 18, 493-508	1.9	154
137	Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. <i>Kidney International</i> , 2000 , 58, 1211-8	9.9	68
136	Target Blood Pressure in Elderly Hypertensive Patients: How Low Should You Go?. <i>Blood Pressure</i> , 2000 , 9, 7-11	1.7	1
135	Cardiac, renal and vascular complications in the diabetic patient. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000 , 1, S21-4	3	
134	Effects of adenosine receptor agonists on efferent renal nerve activity in anesthetized rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 189-94	3.1	1
133	Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 926-31	3.1	21
132	Evidence-based medicine: an educational instrument or a standard for implementation?. <i>Journal of Hypertension</i> , 1999 , 17, 1509-10	1.9	2
131	Impact of hypertension and antihypertensive treatment on organ damage. <i>American Journal of Cardiology</i> , 1999 , 84, 18K-24K	3	94
130	Safety profile of lacidipine: update from a clinical trials database. <i>Drugs</i> , 1999 , 57 Suppl 1, 27-9	12.1	4

129	Risk of major gastrointestinal bleeding with aspirin. <i>Lancet, The</i> , 1999 , 353, 149-150	40	6
128	Perindopril/Indapamide. <i>Drugs</i> , 1999 , 58, 303-304	12.1	
127	Blood pressure control in a hypertension hospital clinic. <i>Journal of Hypertension</i> , 1999 , 17, 835-41	1.9	21
126	Impact of nocturnal fall in blood pressure on early cardiovascular changes in essential hypertension. <i>Journal of Hypertension</i> , 1999 , 17, 1339-44	1.9	30
125	Cardiovascular disease and the kidney: an epidemiologic overview. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33 Suppl 1, S1-6; discussion S41-3	3.1	15
124	Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. <i>Contemporary Clinical Trials</i> , 1998 , 19, 370-90		75
123	Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. <i>Lancet, The,</i> 1998 , 351, 1755-62	40	4439
122	Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 992-1001	15.1	43
121	Clinical Advantages of Lipophilic Dihydropyridines. <i>Blood Pressure</i> , 1998 , 7, 23-26	1.7	5
120	Clinical Advantages of Lipophilic Dihydropyridines. <i>Blood Pressure</i> , 1998 , 7, 23-26	1.7	3
119	Updating recommendations for prevention of coronary heart disease. <i>Journal of Hypertension</i> , 1998 , 16, 1401-2	1.9	
118	Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 1998 , 16, 949-61	1.9	214
117	Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy: the Cardioscreening Study. <i>Journal of Hypertension</i> , 1998 , 16, 681-8	1.9	24
116	Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. <i>Journal of Hypertension</i> , 1998 , 16, 1585-92	1.9	135
115	Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. <i>Journal of Hypertension</i> , 1998 , 16, 1831-8	1.9	32
114	Looking back on three years of Editorship. <i>Journal of Hypertension</i> , 1998 , 16, 1	1.9	5
113	The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. <i>Journal of Hypertension</i> , 1998 , 16, 1667-76	1.9	172
112	24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators Group. <i>Journal of Hypertension</i> , 1997 , 15, 1511-8	1.9	49

111	Effects of antihypertensive treatment on vasopressin secretion and on its osmoregulation in moderate hypertension. <i>Journal of Hypertension</i> , 1997 , 15, 1277-83	1.9	2
110	Blood-pressure control in the hypertensive population. <i>Lancet, The</i> , 1997 , 349, 454-7	40	248
109	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. <i>Lancet, The</i> , 1997 , 350, 757-64	40	2396
108	Electrophysiological evidence of ipsilateral reno-renal reflexes in the cat. <i>Journal of the Autonomic Nervous System</i> , 1997 , 65, 45-8		2
107	Antihypertensive therapy: how to evaluate the benefits. <i>American Journal of Cardiology</i> , 1997 , 79, 3-8; discussion 47-8	3	147
106	Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. <i>Circulation</i> , 1997 , 95, 1464-70	16.7	409
105	Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. <i>Hypertension</i> , 1997 , 30, 1-6	8.5	107
104	Physiological Versus Pathological Hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 145-158	3.6	4
103	Editors?? corner: debating the value of absolute versus relative risk. <i>Journal of Hypertension</i> , 1996 , 14, 681	1.9	5
102	Trials investigating the anti-atherosclerotic effects of antihypertensive drugs. <i>Journal of Hypertension</i> , 1996 , 14, S77-80; discussion S80-1	1.9	10
101	Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database. <i>Journal of Hypertension</i> , 1996 , 14, S15-20	1.9	3
100	Ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 1996 , 14, S61-6; discussion S66-8	1.9	19
99	Left ventricular concentric remodelling and carotid structural changes in essential hypertension. Journal of Hypertension, 1996 , 14, 1441-6	1.9	49
98	Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. <i>Journal of Hypertension</i> , 1996 , 14, 809-11	1.9	14
97	Current position of calcium antagonists in hypertension. <i>Journal of Hypertension</i> , 1996 , 14, S11-5	1.9	8
96	Similarities and differences in structural and functional changes of left ventricle and carotid arteries in young borderline hypertensives and in athletes. <i>Journal of Hypertension</i> , 1996 , 14, 759-64	1.9	28
95	Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 665-71	3.1	1
94	New European studies on atherosclerosis in hypertension. <i>International Journal of Cardiovascular Imaging</i> , 1995 , 11, 115-118		

93	Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. <i>Cardiovascular Drugs and Therapy</i> , 1995 , 9 Suppl 3, 529-31	3.9	1
92	Woven left coronary artery disease. <i>American Journal of Cardiology</i> , 1995 , 75, 311-2	3	16
91	Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. <i>Blood Pressure</i> , 1995 , 4, 148-56	1.7	80
90	Lack of placebo effect on ambulatory blood pressure. <i>American Journal of Hypertension</i> , 1995 , 8, 311-5	2.3	88
89	Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. <i>Journal of Hypertension</i> , 1995 , 13, 1105-12	1.9	76
88	Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 1995 , 13, S35-9	1.9	18
87	Antihypertensive therapy. <i>Journal of Hypertension</i> , 1995 , 13, 1522???1528	1.9	2
86	Ambulatory blood pressure normality. <i>Journal of Hypertension</i> , 1995 , 13, 1377???1390	1.9	306
85	Cardiac and carotid structure in patients with established hypertension and white-coat hypertension. <i>Journal of Hypertension</i> , 1995 , 13, 1707???1711	1.9	41
84	Guidelines for the management of hypertension: the world Health organisation/International society of Hypertension View. <i>Journal of Hypertension</i> , 1995 , 13, S119-S122	1.9	14
83	Cardiac and carotid structure in arterial hypertension and in hypertrophic cardiomyopathy. <i>Cardiology</i> , 1995 , 86, 211-6	1.6	3
82	Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 23, 703-8	3.1	8
81	Hyperlipidemia in the hypertensive patient. American Journal of Medicine, 1994, 96, 3S-8S	2.4	20
80	The 24-hour efficacy of a new once-daily formulation of nifedipine. Italian Nifedipine GITS Study Group. <i>Drugs</i> , 1994 , 48 Suppl 1, 23-30; discussion 30-1	12.1	6
79	Goals of antihypertensive treatment and planning of therapeutic trials. <i>American Journal of Hypertension</i> , 1994 , 7, 13S-15S	2.3	10
78	Treatment Perspectives in Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 24, S61	3.1	31
77	Impairment of the arterial baroreflex during symptomatic and silent myocardial ischemia in humans. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 1866-72	15.1	20
76	The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. <i>Blood Pressure</i> , 1993 , 2, 86-100	1.7	76

75	23 ELSA, European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 1993 , 11, S405	1.9	8
74	190 Ambulatory and home blood pressure reference values. <i>Journal of Hypertension</i> , 1993 , 11, S481	1.9	8
73	Evaluation of organ damage in hypertension. Journal of Hypertension, 1993, 11, 875-82	1.9	6
72	Short- and long-term perspectives of antihypertensive therapy. An introduction. <i>American Journal of Hypertension</i> , 1993 , 6, 2S-5S	2.3	5
71	The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. <i>Clinical and Experimental Hypertension</i> , 1992 , 14, 307-31		16
70	Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. <i>Blood Pressure</i> , 1992 , 1, 205-11	1.7	33
69	Echocardiographic and ultrasonographic evaluation of cardiac and vascular hypertrophy in patients with essential hypertension. <i>Cardiology</i> , 1992 , 80, 305-11	1.6	12
68	Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian Trandolapril Study Group. <i>American Journal of Cardiology</i> , 1992 , 70, 60	D ² 66D	18
67	Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992 , 69, 873-8	3	18
66	Has Antihypertensive Treatment Prevented Vascular Disease or Vascular Events?. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 19, 1-5	3.1	6
65	Regulation of vasopressin release in moderately severe essential hypertension. <i>Clinical Autonomic Research</i> , 1991 , 1, 109-14	4.3	6
64	Treatment of hypertension in the elderly: effects on blood pressure, heart rate, and physical fitness. <i>American Journal of Medicine</i> , 1991 , 90, 12S-13S	2.4	11
63	Left ventricular diastolic function in athletes and borderline hypertensives with mild cardiac hypertrophy. <i>Cardiology</i> , 1991 , 78, 278-81	1.6	6
62	Antihypertensive Treatment. Journal of Cardiovascular Pharmacology, 1991, 17, S48-50	3.1	3
61	Multiple risk factors in hypertension: results from the Gubbio study. <i>Journal of Hypertension</i> , 1990 , 8, S7-12	1.9	51
60	Interactions between the sympathetic nervous system and atrial natriuretic factor in the control of renal functions. <i>Journal of Hypertension</i> , 1990 , 8, 703-10	1.9	7
59	Natriuretic effects of calcium antagonists. Clinical implications. <i>Drugs</i> , 1990 , 40 Suppl 2, 15-21	12.1	7
58	Overview and perspectives of antihypertensive treatment. <i>Drugs</i> , 1990 , 40 Suppl 4, 85-91	12.1	1

57	First-line treatment in hypertension. Role of perindopril. <i>Drugs</i> , 1990 , 39 Suppl 1, 71-5	12.1	2
56	Effects of dilevalol on forearm circulation in essential hypertension. <i>American Journal of Cardiology</i> , 1989 , 63, 21I-24I	3	2
55	Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. <i>American Heart Journal</i> , 1989 , 117, 740-5	4.9	19
54	Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients. Dose-response curves of the different effects. <i>American Journal of Medicine</i> , 1989 , 86, 65-6	2.4	19
53	Value of echocardiographic and ambulatory blood pressure monitoring in hypertension. <i>Clinical and Experimental Hypertension</i> , 1989 , 11, 869-86		3
52	Right ventricular wall thickness and function in hypertensive patients with and without left ventricular hypertrophy: echo-Doppler study. <i>Journal of Hypertension</i> , 1989 , 7, S108-9	1.9	12
51	How much should blood pressure be lowered? The problem of the J-shaped curve. <i>Journal of Hypertension</i> , 1989 , 7, S338-48	1.9	15
50	Baroreceptor mechanisms and the control of vascular resistance. <i>Developments in Cardiovascular Medicine</i> , 1989 , 349-361		
49	Renal hemodynamic effects of dopexamine hydrochloride. <i>American Journal of Cardiology</i> , 1988 , 62, 53C-36C	3	12
48	Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha 1-adrenergic receptor antagonist, trimazosin, in hypertension. <i>Cardiovascular Drugs and Therapy</i> , 1988 , 1, 535-42	3.9	1
47	Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. <i>American Journal of Cardiology</i> , 1988 , 61, 27C-33C	3	15
46	The renin-angiotensin system and the heart. American Journal of Medicine, 1988, 84, 1-2	2.4	2
45	Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. <i>American Journal of Medicine</i> , 1988 , 84, 55-60	2.4	48
44	Baroreflex sensitivity and its evolution during the first year after myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1988 , 12, 629-36	15.1	137
43	Calcium antagonists and neural control of circulation in essential hypertension. <i>Journal of Hypertension</i> , 1987 , 5, S49-55	1.9	9
42	Calcium antagonists and responsiveness of the adrenal glands to aldosterone-releasing stimuli in hypertensive patients. <i>Journal of Hypertension</i> , 1987 , 5, S119-22	1.9	3
41	Afferent Pathways of Neural Reno-Renal Reflexes Controlling Sodium and Water Excretion in the Cat. <i>Journal of Hypertension</i> , 1987 , 5, 417???424	1.9	14
40	Discussion on the natriuretic effect of calcium antagonists. <i>Journal of Cardiovascular Pharmacology</i> , 1987 , 10 Suppl 1, S161-4	3.1	6

39	Renal effects of felodipine in hypertension. <i>Drugs</i> , 1987 , 34 Suppl 3, 59-66	12.1	14
38	Role of calcium antagonists in systemic hypertension. <i>American Journal of Cardiology</i> , 1987 , 59, 130B-1	36B	36
37	Effects of reversible renal denervation on haemodynamic and excretory functions of the ipsilateral and contralateral kidney in the cat. <i>Journal of Hypertension</i> , 1986 , 4, 181-8	1.9	11
36	Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1986 , 8 Suppl 4, S67-74	3.1	31
35	The effects of mianserin therapy on plasma renin activity in depressed patients. <i>Biological Psychiatry</i> , 1986 , 21, 1331-4	7.9	3
34	Participation of the renin-angiotensin system in the maintenance of blood pressure during changes in posture in patients with essential hypertension. <i>Journal of Hypertension</i> , 1985 , 3, 55-61	1.9	11
33	A Re-examination of Stepped-Care. Journal of Cardiovascular Pharmacology, 1985, 7, S126-S131	3.1	16
32	A non-invasive index of leg arterial perfusion pressure during walking, derived from cutaneous toe temperature. <i>Angiology</i> , 1985 , 36, 528-40	2.1	
31	Hemodynamic factors changing blood flow velocity waveform and profile in normal human brachial artery. <i>Angiology</i> , 1985 , 36, 1-8	2.1	18
30	Treatment goals in hypertension. American Journal of Medicine, 1984, 76, 1-3	2.4	6
29	Summary of prazosin lipid studies. American Journal of Medicine, 1984, 76, 122-124	2.4	46
28	Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol. <i>American Heart Journal</i> , 1984 , 108, 1078	-8 ⁴ 3 ⁹	15
27	Arterial baroreceptor control of blood pressure in man. <i>Journal of the Autonomic Nervous System</i> , 1984 , 11, 115-24		24
26	Are There Markers for the Physiopathology of Essential Hypertension? 1984 , 3-12		
25	Arterial Baroreflexes in Human Beings. Developments in Cardiovascular Medicine, 1984, 190-206		
24	Comparison of Cardiovascular, Renal, and Humoral Effects of Acute Administration of Two Calcium Channel Blockers in Normotensive and Hypertensive Subjects. <i>Journal of Cardiovascular</i> <i>Pharmacology</i> , 1982 , 4, S325	3.1	112
23	Modification of arterial baroreflexes by captopril in essential hypertension. <i>American Journal of Cardiology</i> , 1982 , 49, 1415-9	3	75
22	Acute hypotensive and renin-stimulating actions of captopril before and during treatment with a beta-blocking drug. <i>American Journal of Cardiology</i> , 1982 , 49, 1564-5	3	3

Arterial Baroreflexes in Normotensive and Hypertensive Man. *Developments in Cardiovascular Medicine*, **1982**, 34-56

20	Alterations of cardiovascular reflexes in hypertension. <i>Clinical and Experimental Hypertension</i> , 1980 , 2, 451-64		3
19	Methyldopa and neural control of circulation in essential hypertension. <i>American Journal of Cardiology</i> , 1980 , 45, 1237-43	3	21
18	Cardiovascular Regulation during Sleep 1980 , 1-55		37
17	Control of blood pressure by carotid sinus baroreceptors in human beings. <i>American Journal of Cardiology</i> , 1979 , 44, 895-902	3	82
16	Overview of cardiovascular reflexes in hypertension. <i>American Journal of Cardiology</i> , 1979 , 44, 912-8	3	28
15	Prolonged intra-arterial blood-pressure recording in diagnosis of phaeochromocytoma. <i>Lancet, The</i> , 1979 , 2, 1193-4	40	13
14	Central and reflex control of renin release. <i>Progress in Brain Research</i> , 1977 , 47, 397-407	2.9	6
13	Relation between the hypotensive and renin-suppressing activities of alpha methyldopa in hypertensive patients. <i>American Journal of Cardiology</i> , 1977 , 40, 762-7	3	5
12	Control of renin release: a review of experimental evidence and clinical implications. <i>American Journal of Cardiology</i> , 1976 , 37, 675-91	3	65
11	Risk of coronary disease and coronary complications by neural and psychological factors. <i>Advances in Experimental Medicine and Biology</i> , 1975 , 63, 323-35	3.6	2
10	Mechanisms of renal release of renin by electrical stimulation of the brainstem in the cat. <i>Circulation Research</i> , 1974 , 34, 425-34	15.7	76
9	Central and reflex regulation of sympathetic vasoconstrictor activity to limb muscles during desynchronized sleep in the cat. <i>Circulation Research</i> , 1974 , 35, 625-35	15.7	33
8	Emotion and the cardiovascular system in the cat. <i>Novartis Foundation Symposium</i> , 1972 , 8, 201-19		4
7	Relation of cardiovascular changes in fighting to emotion and exercise. <i>Journal of Physiology</i> , 1971 , 212, 321-35	3.9	72
6	Specific appearance of sympathetic cholinergic vasodilatation in muscles during conditioned movements. <i>Nature</i> , 1971 , 232, 124-5	50.4	108
5	Neural and non-neural mechanisms influencing circulation during sleep. <i>Nature</i> , 1969 , 223, 184-5	50.4	46
4	Reflex and brain stem inhibition of sham rage behaviour. <i>Progress in Brain Research</i> , 1968 , 22, 195-205	2.9	2

LIST OF PUBLICATIONS

3 Cardiovascular changes during preparation for fighting behaviour in the cat. *Nature*, **1968**, 220, 1239-40 50.4 34

2	Regulation of circulation by carotid sinus, aortic and cardiopulmonary receptors. <i>Journal of Neural Transmission</i> , 1966 , 28, 197-211	4.3	
1	Autonomic hypothalamic outbursts elicited by cerebellar stimulation. <i>Journal of Neurophysiology</i> , 1954 . 17. 475-83	3.2	124